Retinal Biologics Market Size, Share, and Industry Analysis By Drug Class (Vascular Endothelial Growth Factor (VEGF) Inhibitor and Others), By Disease Indication (Age-Related Macular Degeneration, Diabetic Retinopathy, Macular Edema, and Others (Retinal Vein Occlusion)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global retinal biologics market size was valued at USD 25.23 billion in 2025. The market is projected to grow from USD 27.25 billion in 2026 to USD 50.53 billion by 2034, exhibiting a CAGR of 8.02% during the forecast period.

The global retinal biologics market is growing significantly due to the rising burden of retinal diseases as well as the ageing world population. The field of retinal biologics is a futuristic layer in the development of drugs that can cure different disabling retinal conditions, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO).

The ruthless tempo of technological advancement in biotechnology and massive research and development (R&D) are driving the market to retinal biologics. The improved recombinant DNA technology, production of monoclonal antibodies and fixing genomes are giving rise to new and efficient biologic therapy.

Retinal Biologics Market Driver

Increasing Rates of Retinal Blindness to the Defense Ministry to Expand the Market

The rising burden of retinal diseases has been acting as a primary force behind the retinal biologics business sector. Age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO) are increasing incidences of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) worldwide. It is clearly associated with two big demographic trends: rapid ageing of the world population and an increase in the prevalence of chronic diseases, especially diabetes.

Developments in Biologic Therapies to Advance the Market

The next exciting motivating force is the unstoppable rate of innovation and developments in the sphere of biologic therapies. Current research and development activities are constantly resulting in the discovery and perfection of new biologic agents whose application presents enhanced efficacy, safety, and convenience.

Retinal Biologics Market Restraint

High Treatment Costs to Pose Potential Impediments on this Market

Although the outcomes of retinal biologics are good, one of the major hindering factors to this market is that the treatment costs are high due to their nature. This is due to the high costs of production due to the complex research, development, and manufacturing process and strict quality-control procedures of biologic drugs as compared to their simple counterparts. These exorbitant prices come at a big expense to healthcare systems, insurance agencies and even the individual patients, especially in areas where there are few healthcare resources available or where there is no good and sufficient insurance coverage.

Retinal Biologics Market Opportunity

Individualised Medicine to Create Opportunity in this Market

There is an opportunity that has come up in favour of the retinal biologics market; this is the individualised medicine. The practice does not undermine the old-fashioned one-size-fits-all approach to medical care, tailoring medical solutions to a case-specific patient based on his or her unique genetic code, molecular variant, living environment and character. Personalised medicine will aid in making the diagnosis more precise, and only specific treatment will be provided to those with retinal conditions whose mechanisms are typically complex and diverse.

Segmentation

Key Insights

The report covers the following key insights:

• Market drivers, restraints and opportunities
• Influence of key industrial players and key developments
• Aging Global Population
• Robust R&D Pipeline

Analysis by Drug Class

By Drug Class, the Retinal Biologics market is divided into Vascular Endothelial Growth Factor (VEGF) Inhibitor & Others

The expansion in the retinal biologics business sphere, and, specifically, of the VEGF inhibitor group, is the complicated one. First, agents that block the VEFG, such as aflibercept (Eylea), ranibizumab (Lucentis) and bevacizumab (Avastin, off-label), are currently the first-line standard of care in major retinal diseases.

Analysis by Disease Indication

Based on Disease Indication, the market is divided into Age-Related Macular Degeneration, Diabetic Retinopathy, Macular Edema & Others (Retinal vein occlusion)

One of the leading causes of blindness in aged individuals, particularly in the centre of the retina referred to as the macula, whereby an individual sees in detail and sharpness, is age-related macular degeneration. The retinal biologics market in AMD is experiencing tremendous development since it is coming because of a rapidly ageing population throughout the world.

Dragons of India Diabetic retinopathy is the harmful condition of diabetes and the reason that blinds people. The biologic market of the eye retina in treating DR is expanding at a high pace due to the worrying prevalence of diabetes in the world.

Analysis by Distribution Channel

Based on Distribution Channel, the market is divided into Hospital Pharmacies, Retail Pharmacies & Online Pharmacies

The pharmacies located at the hospitals are the ones with the largest market shares in the circulation of retinal biologics. This domination is through the fact that they possess certain advantages, which are intrinsic to such special and occasionally complex drugs.

On the one hand, it is hospital pharmacies, which already share the lion's share, and on the other hand, it is retail pharmacies which are also involved in the expansion of the retinal biologics market yet in a different way. They must be primarily concerned with giving patients access to less intensively monitored biologics, patients who have access to less intensively monitored drugs and patients getting fewer intensive drugs that are self-administered, among others.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the Retinal Biologics market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The retinal biologics market is dominated by North America, specifically the United States. This has mainly been in terms of its superior healthcare infrastructure, spending on healthcare and a sound research and development (R&D) ecosystem. That area has a high rate of age-related macular degeneration (AMD) and diabetic retinopathy (DR) because of the great number of ageing people and a lot of diabetes cases.

• According to U.S. Food and Drug Administration, there are 6 FDA-approved retinal biologic therapies in U.S.
• According to U.S. Centers of Disease Control and Prevention, 560000 U.S. patients are treated with anti-VEGF biologics annually.

Europe is the next important and increasing market for retinal biologics, almost coming after North America. The territory is well equipped with the healthcare system, high healthcare spending, and a large ageing population, which means that the prevalence of retinal diseases is much higher. Germany, the UK, and France are some of the best markets since they have developed infrastructures that can support the growth of their healthcare industries and invest more in ophthalmology studies.

There is enormous potential in the Asia Pacific region because this region is catching up fast in becoming the fastest-growing region in terms of retinal biologic business. Various parameters that drive this growth include a huge and fast-growing population, escalating disposable incomes and impressive gains in healthcare facilities in nations such as China, India, Japan and South Korea. There is also an alarming increase in the incidence rate of retinal diseases in the region due to the ageing population, especially in combination with the explosive incidence of diabetes.

Key Players Covered

The report includes the profiles of the following key players:

• Regeneron Pharmaceuticals Inc. (U.S.)
• Amgen Inc. (U.S.)
• ANI Pharmaceuticals, Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• BIOSIMILARS NEWCO LIMITED (a Biocon Biologics company) (U.K.)
• Novartis AG (Switzerland)
• Samsung Bioepis. (South Korea)
•  F. Hoffmann-La Roche Ltd (Switzerland)

Key Industry Developments

• In May 2024, Merck acquired privately held, ophthalmology-orientated biotechnology company EyeBio in a transaction with a value of up to 3 billion dollars, including an upfront payment and milestone payments.
• Recently, Teva Pharmaceuticals has extended its biosimilar portfolio and commercial reach in the market by partnering both with Formycon AG and Samsung Bioepis. In January 2025, Teva entered into a semi-exclusive commercialisation agreement with Formycon AG (and its commercialisation partner Klinge Biopharma) on FYB203, Formycon's biosimilar product candidate to Eylea (aflibercept) in major markets in Europe, including Israel.